Hopes were running high at the end of the 20 th century. The newly hatched internet economy took off, the Cold War was consigned to history, two separate teams were racing to sequence the human genome, and once that was in the databanks, surely we would understand much more about our diseases and develop new cures based on the genetic insights. And Al Gore might become US president and do something about climate change.
Fifteen years on, humanity has achieved very little of what we may have reasonably hoped for at the approach of the millennium. Genomics has delivered unprecedented insights into evolution and functional biology, but fallen short on the headline goal of addressing common medical problems like cancer and heart disease. The idea of repairing defective genes causing diseases suffered even more disappointment.
In September 1999, Jesse Gelsinger, an 18-year-old patient with ornithine transcarbamylase deficiency taking part in a clinical trial for a gene therapy treatment, died after a severe immune response to the adenovirus vector used to smuggle the repair genes into his liver cells. Further setbacks followed when other patients developed cancers blamed on the treatment. Thus, as the human genome reached completion, the project of repairing genomes had to go back to the drawing board and come back with new methods.
More than a decade later, gene therapy is now returning to the spotlight with safer methods, a wider range of target diseases, and a growing number of successful clinical trials. In November 2012, the EU's licensing of the Glybera gene therapy developed by the company uniQure signalled the definitive comeback of the idea. The wide range of therapies now in development and in clinical trials seems to suggest that many more will follow.
New vectors
The death of Jesse Gelsinger, as well as the subsequent cases of cancers resulting from treatment, were all blamed on the vectors used. Adenovirus can trigger an immune response, and retroviruses can incorporate themselves at Feature unsuitable locations activating tumour development.
Since then, adeno-associated virus (AAV) has become the preferred choice of viral vector, as it causes no known side-effects and only a very mild immune response. The only problem so far identified with this benign human virus is that it is fairly widespread, to the extent that many patients will already have immunity against some strains of the virus. Researchers can sidestep this problem by choosing a rare strain of the virus, or by using it in the brain where the neutralising antibodies don't patrol, but for wider clinical applications it remains a limitation.
The first licensed gene therapy treatment, uniQure's Glybera, uses a vector derived from AAV serotype 1. It treats a rare inherited disease, lipoprotein lipase (LPL) deficiency, where the absence of a fat-digesting enzyme leads to inflammation of the pancreas. Injection of the vector carrying the LPL gene enables expression of the enzyme in muscles.
Many other treatments using AAV-based vectors are currently undergoing or have recently completed clinical trials, including therapies for hemophilia, cystic fibrosis, and age-related macular degeneration. However, there is still a case for developing alternative, non-viral New vectors, new approaches, new disease targets and the first EU licence for a gene therapy have injected a much-needed dose of fresh hope into this field. Investment is flowing and further therapies are expected to follow. Michael Gross reports.
New hopes for gene therapy
Human helix: High hopes were placed on the rapid advances in molecular biology, but clinical applications of gene therapy were delayed by early setbacks. (Photo: Courtesy of Genentech.) delivery vectors, and there is a wide range of chemical approaches that could be applied to this task.
As DNA carries negative charges by default, it readily self-assembles with cationic polymers, which can be used for the formation of nanoparticles carrying the gene of interest. The group of Jordan Green at Johns Hopkins University in Baltimore, Maryland, USA, has developed a polymer library based on a family of cationic linear polymers, the poly -aminoesters. As with natural peptides and proteins, a variety of sidechains can equip these polymers with a wide range of chemical properties and structures.
Green's lab has shown that these polymers self-assemble and encapsulate up to 100 plasmids in each nanoparticle. The resulting particles are non-toxic and biodegradable, with half-lives in the range of a few hours. In a study directed at applications against human brain cancers, the researchers found that the nanoparticles have an intrinsic preference to incorporate themselves into primary cancer cells rather than into the neural progenitor cells, removing the need for specific targeting ligands (ACS Nano (2014) 8, 5141-5153) .
Other types of molecules, including lipids, peptides, sugars and dendrimers (polymers with branching rather than linear connectivity), are also being investigated for the development of new vectors for gene therapy. Dendrimers, for instance, are discussed as a promising option for eye diseases (J. Pharm. Pharmacol. (2013) 66, 542-556) .
Finally, some researchers have combined the molecular design approach with the idea of using viral vectors by building novel, viruslike shells from scratch. The group of Renko de Vries at Wageningen University, Netherlands, used the cylindrical shell of tobacco mosaic virus, a much-studied example of natural protein self-assembly, as a model to build an entirely new DNAcoating shell from three simple protein building blocks (Nat. Nanotechnol. (2014) DOI: 10.1038/nnano.2014.169). A sequence of lysine residues provides the cationic sites that bind the DNA. This is followed by a sequence gleaned from natural silk, providing structural stability with a high percentage of alanine and glycine. By varying the number of these silk-like repeats, the researchers could fine-tune the selfassembly process. The third part of the sequence, displayed on the outside of the virus-like rod, can be freely manipulated to guide the behaviour of the rods in suspension, e.g. stop them from aggregating.
So far, this recent work has focused on the self-assembly process itself and the packaging of DNA, but it could be easily developed into new vectors for gene therapy. In a similar approach, Kenneth Woycechowsky's group at the University of Utah at Salt Lake City, USA, has mutated a non-viral protein to enable it to form virus-like capsid structures (J. Am. Chem. Soc. (2012) 134, 13152-13155) . The idea is to take the benefit of viral packaging and delivery mechanisms without the disadvantage of recognition by the immune system.
New approaches
The first gene therapy projects typically involved providing a spare copy of the defective gene. Recent progress has added other possibilities, including editing genes, silencing them, and introducing toxic genes to specifically kill cancer cells.
One promising approach to gene editing is the CRISPR/Cas9 system, which evolved in bacteria as a kind of adaptive immune system against phages. The editing technique derived from it involves targeting an endonuclease, Cas9, directed by a guide RNA, to a specific site in the genome where it creates a double-strand break. The versatility of the technique relies on the fact that the guide RNA can be designed to target virtually any site in any known genome. If desired, Cas9 can also be combined with different guide RNAs to target several sites at once. The break can then be repaired either non-homologously, resulting in an insertion or deletion, or in a templatedirected way. "Genomic editing to cure diseases caused by single gene mutations, as shown in our recent study of Duchenne muscular dystrophy, represents a powerful approach to eliminate diseasecausing genetic lesions and allow for permanent restoration of normal cellular function," Olson explained. He showed himself optimistic that the approach will become medically useful: "While there will be hurdles, such as scale up and efficiency of cellular delivery of gene editing components, I believe these can be overcome in the very near future," he concluded.
Genome editing in the human germline is not feasible at the moment and would raise ethical questions if it became possible. However, the observation that muscle function can be rescued with only a small percentage of repaired cells also opens up the possibility of applying gene therapy for muscular dystrophy at the somatic level.
Another new approach that has broadened the concept of gene therapy is the introduction of genes with the intention to kill cells. For instance, if genes triggering apoptosis could be targeted specifically at cancer cells, and more importantly, at the progenitor cells from which new tumours will grow, this could be a breakthrough in cancer treatment.
For example, one of the diseases that Jordan Green's group hopes to fight with the novel polymer nanoparticles mentioned above is glioblastoma, which is both the most common kind of primary brain tumour in adults and the most deadly one. In spite of all the surgery, radiation and chemotherapy that modern medicine has thrown at this problem, half of the patients die within 15 months of diagnosis.
Typically, surgical removal of the tumour leaves behind brain tumour initiating cells (BTICs), which may lead to a recurrence of the disease. Green's nanoparticles have shown the ability to incorporate specifically into these BTICs in vivo, opening up the possibility of delivering apoptosis genes locally during tumour surgery to prevent the disease from coming back.
A related way of manipulating gene expression in vivo is RNA interference (RNAi), which was similarly greeted with high hopes after its discovery in 1998 but has experienced some setbacks. RNAi, which won its discoverers the Nobel Prize in 2006, is a supremely elegant gene silencing method that works like magic in a wide range of laboratory systems. However, like gene therapy, it experienced trouble in the development of suitable delivery systems for medical applications. Like gene therapy, the RNAi field is now looking to nanoparticle solutions for the safe delivery of RNA into the targeted cells. Daniel Anderson's group at MIT has recently demonstrated successful delivery of siRNA to endothelial cells in vivo using nanoparticles formed from low molecular weight polymers (Nat. Nanotechnol. (2014) 9, 648-655).
The MIT spin-out company Alnylam, which has survived some serious setbacks since its foundation in 2002, is now conducting advanced clinical trials of an RNAi treatment for familial amyloid polyneuropathy (FAP), which is expected to reduce the production of harmful misfolded protein in the patients' livers by 80%. Further RNA therapies in the company's pipeline include treatments for hemophilia, hepatitis B, and high cholesterol levels.
New disease targets
The initial idea behind gene therapy was to replace or repair a single faulty gene. This now appears simplistic and limiting, as the analyses of the human genome have failed to reveal important single-gene problems beyond those that were known already. Instead, we now know that the genetic basis of disease is highly complex and involves not just gene sequences but also regulatory elements in the non-coding regions as well as epigenetic markers.
Even treatments targeting a single gene in the traditional sense can have a broader benefit, as a recent study from the group of Yuji Yamanashi at the University of Tokyo has shown (Science (2014) 345, 1505-1508) . The researchers set out repair the gene DOK7 in a mouse model of myasthenia, a disease linked to a weakness in the neuromuscular junction. Introduction of the DOK7 gene successfully cured the disease caused by a defect in this very gene.
Beyond that anticipated finding, however, the researchers also found that the treatment enlarged the neuromuscular junction of wild-type controls. They hypothesized that this effect might also be beneficial in animals with unrelated neuromuscular disorders, which they could confirm for Emery-Dreifuss muscular dystrophy. The benefit could also apply to amyotrophic lateral sclerosis (ALS). While the mechanism by which the gene therapy triggers these beneficial effects remains to be elucidated, this unexpected finding suggests that even gene therapy for rare specific gene defects may in some cases have broader applicability.
Recent developments have broadened the scope of gene therapy beyond the small group of simple diseases caused by a single gene defect. As outlined above, the possibility to introduce apoptosis genes into specific cells has opened up applications in cancer therapy. The company that got the first regulatory approval for gene therapy, uniQure, also has advanced development programmes targeting diseases like intermittent porphyria, Sanfilippo B, hemophilia B and Parkinson's disease.
Surprisingly, even patients with infectious diseases can benefit from gene therapy. Efforts are underway to use a rare gene variant that makes some people immune to HIV in the treatment of patients who have contracted the virus. An initial experimental treatment of a patient with leukaemia and HIV who received a bone marrow transplant from a donor with the resistance gene variant suggested that the idea works in principle, but that a less invasive implementation needs to be found.
In March this year, researchers reported first results of a phase I clinical study based on ex vivo gene editing to introduce the HIV-resistant trait into a population of lymphocytes which were then re-injected to the patients. While the trial was designed only to establish the safety, not the efficacy of the treatment, observations were encouraging, as several patients were able to keep the virus in check without their usual daily drugs (N. Engl. J. Med. (2014) 370, 901-910) .
The broad range of success stories emerging in the last few years has given researchers in the field fresh optimism, mirrored also in the activity of biotech entrepreneurs and venture capital firms. In spite of its troubled beginnings, it looks like gene therapy is now set to take up a significant role in clinical practice, fulfilling treatment needs that have proven elusive to conventional therapies.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk could not be among the best? The 'pull' was my enjoyment of human anatomy, combined with the realization that because of my good fortune to be involved with Richard Leakey's research team, I had the unique opportunity to help interpret the new evidence they were unearthing.
Why did you choose to work on skulls and teeth? I didn't. I was one of three anatomists (the others were Michael Day and Alan Walker) Richard Leakey had invited to describe and interpret the hominin fossils recovered from Lake Rudolf. The majority of the fossils were from the skull and dentition, but each of us wanted to work on the limb bones. In 1972, we met in New York to discuss the impasse, but none of us would give in. So, not a little frustrated, Richard broke three matches into different lengths and made us draw. Mine was the shortest match, so I had no choice but to work on the cranial remains. This task, which involved determining how many taxa were represented among the hominin cranial fossils, led to the topic of my PhD, sexual dimorphism, and my interest in patterns of intra-versus interspecific variation. Why did you initially choose medicine as a career? I was hopeless at languages -I had a debilitating stammer -and in those days you learned languages by reading out loud from a book and that was beyond me. But I was reasonably good at science and geography. My method for finding a possible career was unconventional but practical. My parents owned a grocery store. One of my chores was to deliver groceries on a bicycle. In general, when I delivered groceries to the houses of lawyers and accountants, I felt my efforts were unappreciated. There was, however, a medical household where I would always be given a glass of lemonade, and where my nascent interest in medicine was encouraged -Bill Clark even gave me his copy of a book of essays by Sir William Osler. It is still on my bookshelf. His kindness and solicitude are why I decided to become a doctor.
Why did you switch to paleoanthropology? There were elements of 'push' and 'pull': the 'push' was that I had the good fortune to be apprenticed to a surgeon whose diagnostic and clinical skills were legendary. However, he was so good that it was pretty clear to me that, no matter hard I worked at it, I was unlikely to be as good a surgeon as he was. And what was the point of doing something like surgery if you
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